Maria R. Luquin
Pamplona, NC 31008, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
An injectable nanoreinforced hydrogel for combined GDNF-loaded nanoparticles and mesenchymal stem cell therapy in Parkinson's disease.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: April 10, 2026
Targeting Metabolic Dysfunction in Parkinson's Disease: The Role of GLP-1 Agonists in Body Weight Regulation and Neuroprotection.
Journal: Current diabetes reports
Published: August 25, 2025
FKBP51 inhibition ameliorates neurodegeneration and motor dysfunction in the neuromelanin-SNCA mouse model of Parkinson's disease.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: August 07, 2024
Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models.
Journal: Neurobiology of disease
Published: January 31, 2023
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Journal: The New England journal of medicine
Published: August 03, 2022
Prevalence of Advanced Parkinson's Disease in Patients Treated in the Hospitals of the Spanish National Healthcare System: The PARADISE Study.
Journal: Brain sciences
Published: September 29, 2021
Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy.
Journal: Translational neurodegeneration
Published: September 29, 2021
Excess abdominal fat is associated with cutaneous allodynia in individuals with migraine: a prospective cohort study.
Journal: The journal of headache and pain
Published: October 29, 2019
Cardiac sympathetic innervation in the MPTP non-human primate model of Parkinson disease.
Journal: Clinical autonomic research : official journal of the Clinical Autonomic Research Society
Published: May 16, 2019
Small fiber neuropathy and phosphorylated alpha-synuclein in the skin of E46K-SNCA mutation carriers.
Journal: Parkinsonism & related disorders
Published: January 10, 2019
The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia.
Journal: Neurobiology of disease
Published: April 17, 2018
Last Updated: 09/26/2026